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Inhibiting expression of huntingtin (HTT) protein is a
promising strategy for treating Huntington’s disease
(HD), but indiscriminant inhibition of both wild-type
and mutant alleles may lead to toxicity. An ideal
silencing agent would block expression of mutant
HTTwhile leaving expression of wild-type HTT intact.
We observe that fully complementary duplex RNAs
targeting the expanded CAG repeat within HTT
mRNA block expression of both alleles. Switching
the RNAi mechanism toward that used by miRNAs
by introducing one or more mismatched bases into
these duplex RNAs leads to potent (<10 nM) and
highly selective (>30-fold relative to wild-type HTT)
inhibition of mutant HTT expression in patient-
derived cells. Potent, allele selective inhibition of
HTT by mismatched RNAs provides a new option
for developing HD therapeutics.
INTRODUCTION
Huntington’s disease (HD) is a neurodegenerative disorder with
an incidence of 5–10 per 100,000 individuals in Europe andNorth
America (Walker, 2007). HD is characterized by progressive
neurodegeneration resulting in chorea, dystonia, and cognitive
or psychiatric disturbances. Symptoms worsen until death,
10–20 years after disease onset. Genetic tests and palliative
treatments exist, but there are no curative therapies. Effective
therapeutic strategies that delay the onset of HD remain a major
unmet need.
HD is caused by a dominant heterozygous expansion of a CAG
trinucleotide repeat that encodes multiple glutamine residues
within the gene encoding huntingtin (HTT) protein (MacDonald
et al., 1993). The mutant HTT allele in patients with HD contains
tracts of more than 39 consecutive glutamine codons. Most
patients have 50 repeats or less, but some patients can have
as many as 120. Higher numbers of repeats correlate with earlier
onset of disease (Kremer et al., 1994; Duyao et al., 1993).
Although the exact molecular defects caused by mutant HTT
expression are not definitively known, aggregation of polyglut-
amine fragments of HTT induces plaque formation (SanchezChemistry & Biology 17, 1183–118et al., 2003). HTT is expressed in many tissues, but the central
nervous system and brain are especially sensitive to expression
of mutant HTT, with striatal neurons suffering the most degener-
ation (Reddy et al., 1998).
Developing agents to lower levels of mutant HTT in patients
offers one strategy for developing medications to treat HD (Pfis-
ter and Zamore, 2009). Lower HTT levels should delay or prevent
aggregation of polyglutamine fragments, slow plaque formation,
and reduce damage to cells. This hypothesis has been tested in
several animal models using both antisense oligonucleotides
and duplex RNAs, and reducing levels of mutant HTT has been
shown to alleviate symptoms and prolong survival (Harper
et al., 2005; DiFiglia et al., 2007; Boudreau et al., 2009; Gagnon,
2010). These data suggest that controlling mutant HTT in
patients would be a major therapeutic advance.
Typically, agents that silence gene expression block expres-
sion of both alleles of the target gene. However, wild-type HTT
may play a role in normal adult function (Nasir et al., 1995; White
et al., 1997), and strategies that reduce expression of both the
wild-type and mutant alleles may cause side effects in patients.
Although it is possible that an agent that inhibits both wild-type
and mutant HTT might be both safe and effective (Drouet
et al., 2009; Boudreau et al., 2009), an ideal agent would selec-
tively reduce mutant HTT expression but not alter wild-type
protein levels. Because of the lack of curative treatments for
HD, it is essential that both allele-selective and nonallele-selec-
tive approaches for reducing mutant HTT levels be pursued.
Strategies have been developed that achieve allele-selective
inhibition of HTT expression. One approach takes advantage
of the fact that themutant HTT allele often contains single-nucle-
otide polymorphisms that distinguish it from the wild-type allele,
allowing short-interfering RNAs (siRNAs) to selectively target the
mutant gene (Miller et al., 2003; Schwarz et al., 2006; van Bilsen
et al., 2008; Pfister et al., 2009; Zhang et al., 2009). The identity of
SNPs varies, with 86% of European Caucasian patients sharing
26 different SNPs (Lombardi et al., 2009), but some SNPs are
common, and only five duplex RNAs would be sufficient to treat
75% of patients with HD (Schwarz et al., 2006). Although target-
ing SNPs is promising, the need to develop several different
agents complicates development and suggests a continuing
need for new strategies for silencing HD.
Another strategy involves single-stranded oligomers comple-
mentary to the expanded CAG repeat within HTT mRNA that
achieve potent and selective inhibition of HTT expression (Hu
et al., 2009a, 2009b, 2009c). This strategy would require just8, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1183
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Figure 1. Allele-Selective Inhibition by
Mismatch-Containing Duplex RNAs
Schemes showing recognition of a (A) perfectly
complementary duplex leading to cleavage of
mRNA and (B) mismatch-containing duplex
leading to inhibition of translation. Effect on HTT
expression from adding duplex RNAs (C) P9, (D)
REP, and (E) PM3 to GM04281 cells, or (F) P9 to
GM04717 cells. Data describing the selectivities
and potencies of other duplexes can be found in
Table 1.
See also Figure S1. Error bars for data derived
from western analysis are standard error of the
mean (SEM).
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Inhibition of Mutant Huntingtin Expressionone oligomer to treat the entire population of patients with HD.
Oligomers that target the long (250 repeat) CUG repeat within
the 30 untranslated region (30-UTR) of DM protein kinase, the
cause of myotonic dystrophy, have also been shown to be bio-
logically active (Wheeler et al., 2009). However, after testing
several different chemically modified oligomers complementary
to the CAG repeat in HTT mRNA, it has been difficult to improve
upon the potencies and selectivities that were observed initially
(Gagnon et al., 2010).
Developing highly potent and selective methods for silencing
the mutant allele of HTT remains challenging. Based on the
potency of duplex RNA and the length of CAG repeat, we asked
whether we could achieve the selectivity by targeting CAG repeat
region using siRNA.We observed that these siRNAs were potent
inhibitors of HTT but showed little selectively between themutant
and wild-type alleles (Hu et al., 2009a, 2009c).
RNAi can function through two distinct mechanisms (Filipo-
wicz et al., 2008; Kurreck 2009). If the duplex RNA is fully
complementary to its mRNA target, human argonaute 2
(AGO2) protein cleaves the mRNA at the phosphodiester linkage
opposite siRNA bases 10 and 11 (Figure 1A) (Liu et al., 2004).
This mechanism is used by the siRNAs commonly used in
laboratories for gene silencing.1184 Chemistry & Biology 17, 1183–1188, November 24, 2010 ª2010 Elsevier Ltd All rights reHowever, mismatches between the
duplex RNA and mRNA target disrupt
interactions at the catalytic center of
AGO2 and make cleavage less efficient
(Figure 1B) (Du et al., 2005; Wang et al.,
2008). Gene silencing can still occur
but may involve inhibition of ribosome-
mediated translation or reduced mRNA
stability rather than cleavage of the
mRNA target. This mechanism is
commonly used by naturally occurring
miRNAs to inhibit expression of endoge-
nous genes and regulate cell physiology.
In addition the expanded CAG repeat
offers multiple target sequences for
finding complementary duplex RNAs,
and it is known that the binding of multiple
mismatch-containing duplex RNAs to
mRNA can yield synergistic increases in
potency for miRNAs (Grimson et al.,
2007). The miRNA-like mechanism issimilar to the mechanism of single-stranded PNAs, which also
block translation rather than cause mRNA cleavage (Knudsen
and Nielsen, 1996), raising the possibility that miRNA-like
duplexes might be better candidates for achieving allele selec-
tivity. We hypothesized that deliberately switching the RNAi
mechanism would be advantageous for discriminating among
closely related RNA targets and achieving allele-selective
regulation of disease genes.
Here, we test mismatch-containing duplex RNAs complemen-
tary to the CAG repeat. We find that they are potent, versatile,
and selective agents for blocking expression of the mutant
HTT allele.
RESULTS AND DISCUSSION
We transfected duplex RNA P9 (single mismatch at base 9 within
the guide strand/antisense relative to the mRNA target) (Table 1)
into a patient-derived fibroblast cell line GM04281 (69 CAG
repeats/mutant; 17 repeats/wild-type allele). P9 possessed
high selectively, >31-fold, for inhibition of mutant versus wild-
type HTT (Figure 1C). Fully complementary RNA REP and sister
compounds REPC and REPU that were shifted to start with C or
U showed selectivities of less than 2- to 3-fold (Figure 1D; seeserved
Table 1. siRNAs Targeting the HTT CAG Repeat Region
RNA Sequence
Position of
mismatch Tm,C mut IC50 (nM) wt IC50 (nM) Selectivity
siRNA Fully Complementary to CAG Repeat Region (only guide strand is shown)
REP GCUGCUGCUGCUGCUGCUGTT 86.8 5.0 ± 3.0 13 ± 5.0 3
REPC CUGCUGCUGCUGCUGCUGCTT 86.6 5.4 ± 1.6 12 ± 2.6 2
REPU UGCUGCUGCUGCUGCUGCUTT 86.5 5.6 ± 1.1 9.8 ± 1.2 2
siRNA Containing One Mismatched Base on Both Strands (only guide strand is shown)
P4 GCUACUGCUGCUGCUGCUGTT 4 84.0 4.1 ± 2.0 16 ± 7.4 4
P5 GCUGAUGCUGCUGCUGCUGTT 5 83.2 14 ± 2.9 >100 >7
P6 GCUGCAGCUGCUGCUGCUGTT 6 85.1 No inhibition No inhibition -
P7 GCUGCUACUGCUGCUGCUGTT 7 82.7 13 ± 5.6 53 ± 13 4
P8 GCUGCUGAUGCUGCUGCUGTT 8 83.8 5.1 ± 0.7 >100 >20
P9 GCUGCUGCAGCUGCUGCUGTT 9 86.7 3.2 ± 0.9 >100 >31
P10 GCUGCUGCUACUGCUGCUGTT 10 83.5 4.0 ± 2.8 >100 >25
P10R GCUGCUGCUUCUGCUGCUGTT 10 78.0 3.5 ± 2.2 >100 >27
P11 GCUGCUGCUGAUGCUGCUGTT 11 83.7 2.7 ± 0.8 >100 >37
P12 GCUGCUGCUGCAGCUGCUGTT 12 85.6 3.7 ± 1.9 33 ± 12 9
P13 GCUGCUGCUGCUACUGCUGTT 13 82.8 5.3 ± 1.1 26 ± 8.4 5
P16 GCUGCUGCUGCUGCUACUGTT 16 76.4 1.0 ± 0.8 7.0 ± 1.3 7
siRNA Containing Multiple Mismatched Bases on Both (only guide strand is shown)
P910 GCUGCUGCAACUGCUGCUGTT 9,10 83.5 4.5 ± 0.9 >100 >22
PM3 GCUGCUGCAAAUGCUGCUGTT 9,10,11 79.9 3.2 ± 1.0 >100 >31
PM4 GCUGCUGAAAAUGCUGCUGTT 8,9,10,11 76.4 4.8 ± 1.6 >100 >21
RM3 GCUACUGCUACUGCUACUGTT 4,10,16 83.0 63 ± 42 >100 >2
RM4 GCAGCUGUUGCUACUGUUGTT 3,8,13,17 78.0 No inhibition No inhibition -
siRNA Containing One or Two Mismatched Bases on Only One Strand
P9a GCUGCUGCUGCUGCUGCUGTT TTCGACGACGUCGACGACGAC 9 79.4 2.0 ± 0.6 8.9 ± 1.3 4
P10a GCUGCUGCUGCUGCUGCUGTT TTCGACGACGAUGACGACGAC 10 80.8 5.4 ± 1.4 27 ± 12 5
P910a GCUGCUGCUGCUGCUGCUGTT TTCGACGACGUUGACGACGAC 9,10 77.6 2.7 ± 0.5 9.9 ± 2.0 4
P9b GCUGCUGCAGCUGCUGCUGTT TTCGACGACGACGACGACGAC 9 80.0 2.3 ± 1.5 >100 >43
P10b GCUGCUGCUACUGCUGCUGTT TTCGACGACGACGACGACGAC 10 77.6 6.8 ± 1.5 >100 >15
P10R –b GCUGCUGCUUCUGCUGCUGTT TTCGACGACGACGACGACGAC 10 75.4 2.3 ± 0.5 >100 >43
P11b GCUGCUGCUGAUGCUGCUGTT TTCGACGACGACGACGACGAC 11 77.5 10 ± 2.4 >100 >10
P910b GCUGCUGCAACUGCUGCUGTT TTCGACGACGACGACGACGAC 9,10 74.1 6.6 ± 0.6 >100 >15
REPC-b CUGCUGCUGAUGCUGCUGCTT TTGACGACGACGACGACGACG 10 77.2 7.5 ± 2.1 >100 >13
REPU-b UGCUGCUGCAGCUGCUGCUTT TTACGACGACGACGACGACGA 10 80.2 4.0 ± 1.2 >100 >25
Noncomplementary Control siRNA
CM GCUAUACCAGCGUCGUCAUTT 80.0 - - -
siRNA Tested on Fibroblasts of Patients with HD with Shorter CAG Repeat
P9 In GM04719, 44 mut/15 wt 4.5 ± 1.3 >100 >22
P910 In GM04719, 44 mut/15 wt 8.9 ± 2.2 >100 >11
P9 In GM04717, 41 mut/20 wt 2.6 ± 0.6 71 ± 43 27
P910 In GM04717, 41 mut/20 wt 4.2 ± 0.8 57 ± 16 13
The guide strand is shown from 50 to 30. Mismatched bases are underlined and in italics. Both strands of the duplexes containing two TT overhang.
siRNAs were tested in fibroblast GM04281 of patients with HD (mutant [mut] allele/69 CAG, wild type [wt]/17 CAG repeats) unless otherwise noted.
Selectivity is calculated by dividing the IC50 for inhibition of wild-type HTT versus the IC50 for inhibiting expression of the mutant HTT protein.
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Inhibition of Mutant Huntingtin ExpressionFigure S1A available online). These data demonstrated that
mismatch-containing RNAs widen the window for achieving
selective inhibition.
We tested duplexes containing mismatches placed sequen-
tially throughout the RNA duplex (Table 1; Figures S1B andChemistry & Biology 17, 1183–118S1C). siRNAs P8, P9, P10, P10R, and P11 containing centrally
located mismatches yielded greater selectivity for inhibition of
mutant versus wild-type HTT expression (>20- to >37-fold)
than duplexes P4, P5, P6, P7, P12, P13, and P16 with
mismatches closer to the 50 or 30 termini (4- to 9-fold). Mutations8, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1185
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Figure 2. Mechanism of Allele-Selective
RNAs
(A and B) Effect on mutant and wild-type HTT
expression after treatment with duplex RNAs that
contain a mismatched base in either the (A)
passenger strand, P9a, or (B) guide strand, P9b.
(C) qPCR analysis of effect on HTT mRNA levels
after treatment of increasing amount of siRNAs
siHdh1, REP, and P9.
(D) Effect of varied siRNAs (12 nM) on HTT mRNA
levels measured by qPCR. (E) Effect of allele-
selective duplex RNAs (25 nM) on expression of
other genes containing regions with CAG repeats.
CM, a duplex RNA not complementary to HTT
mRNA; siHdh1, an siRNA that is complementary
to HTT mRNA outside of the CAG repeat region
(Omi et al., 2005).
See also Figure S2. Error bars for data derived from
western analysis are standard error of the mean
(SEM). Error bars for qPCR data are standard
deviation.
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Inhibition of Mutant Huntingtin Expressionwithin the RNA duplex disrupt cleavage of the mRNA by RISC
(Du et al., 2005; Wang et al., 2008), and our data indicated that
shifting the mechanism for RNAi away from mRNA cleavage
improves selectivity.
We tested duplexes containing several mismatches to estab-
lish the breadth of modifications that might be tolerated. When
multiple mismatches are spread throughout the RNA duplex,
potencies decrease substantially (Figure S1D). However, when
two, three, or four contiguous mismatches are clustered within
the central portion of the siRNA, we observed potent and selec-
tive inhibition of mutant HTT (Figures 1E; S1E). The ability to
introduce as many as four mismatches provides great flexibility
for optimizing selective compounds for in vivo investigation
and offers additional evidence for a mechanism that does not
depend on RISC-mediated cleavage.
Half of patients with HD have mutant alleles with <45 CAG
repeats (Duyao et al., 1993; MacDonald et al., 1993). To deter-
mine whether our strategy might be applied to a broad range of
patients with HD, we tested mismatch-containing duplex RNAs
in GM04719 (44 repeats/mutant; 15 repeats/wild-type allele)
and GM04717 (41 repeats/mutant; 20 repeats/wild-type allele)
patient-derived fibroblast cells. Previously, we had observed
that single-stranded PNAs could achieve >1.8- and >1.5-fold
selectivities for GM04719 and GM04717 cells, respectively.1186 Chemistry & Biology 17, 1183–1188, November 24, 2010 ª2010 Elsevier Ltd All rights rUsing mismatch-containing duplex
RNAs, we observed robust selectivities
(>10- to 20-fold) and potencies for inhibit-
ing mutant HTT (<10 nM) in both cell lines
(Figure 1F and Table 1; Figures 1F and
S1G), demonstrating substantial allele-
selective inhibition across the full spec-
trum of CAG repeat lengths encountered
in patients.
Duplex RNAs consist of a guide strand
(antisense relative to the mRNA) and
a passenger strand (sense relative to the
mRNA). The guide strand is complemen-
tary to the target mRNA, is loaded intothe RISC complex, binds to the mRNA target, and should be
more sensitive to the introduction of mutations than the
passenger strand. Duplexes P9a, P10a, and P910a with muta-
tions on the passenger strand possessed relatively low selectiv-
ities (4- or 5-fold) (Figure 2A; Figure S2A). Duplexes P9b, P10b,
P10R/b, P11b, and P910b with mutations on the guide strand
had selectivities up to >43-fold (Figure 2B; Figures S2B and
S2C), indicating that the mechanism of selectivity requires
mutation of the guide strand.
We used quantitative PCR (qPCR) to evaluate levels of HTT
mRNA after addition of mismatch-containing siRNA P9, fully
complementary siRNA REP, and siRNA siHdh1 (Omi et al.,
2005) that recognizes HTT mRNA at a sequence outside of
the CAG repeat region. Relative to addition of REP or siHdh1,
addition of P9 caused a significantly lower reduction in HTT
mRNA levels (Figure 2C). Mismatch-containing RNAs P910,
PM3, and PM4 also resulted in little alteration of HTT mRNA
levels (Figure 2D). The finding that mismatch-containing duplex
RNAs yield little decrease of HTT mRNA is consistent with
a mechanism of action that involves blocking translation rather
than mRNA cleavage.
Several physiologically important genes contain CAG repeats,
and inhibiting their expression would be detrimental. We exam-
ined expression of two important repeat-containing genes,eserved
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Inhibition of Mutant Huntingtin ExpressionTATA box-binding protein (TBP) (19 CAG repeats) and FOXP2
(40 glutamines encoded by a mixed CAG and CAA repeats).
We observed that expression of these proteins was not inhibited
by a panel of duplex RNAs that were added at 25 nM, a concen-
tration substantially above their IC50 values for inhibiting mutant
HTT (Figure 2E). We had previously observed that single-
stranded oligomers targeting the CAG repeat that reduce levels
of mutant HTT protein also did not affect expression of a panel of
CAG repeat-containing genes (Hu et al., 2009c).
There are no curative treatments of HD, and strategies for
reducing expression of HTT offer a direct approach toward miti-
gating or preventing the course of the disease. Improved delivery
technologies (Smith et al., 2006; De Souza et al., 2009) are making
nucleic acids a promising approach for neurodegenerative
diseases. A Phase I clinical trial for amyotrophic lateral sclerosis
(ALS) using an antisense oligonucleotide delivered directly into
the central nervous system has recently been initiated (http://
isispharm.com).Given theobviouspotential forbenefits topatients
from reducing HTT levels and improving methods for nucleic acid
delivery to the brain, approaches that use duplex RNAs or anti-
sense oligonucleotides to silence HTT expression are a promising
approach toward meeting a major unmet therapeutic need.
It is possible that nonallele-specific inhibition of both wild-type
and mutant HTT protein may be an adequate therapeutic
approach. Theremay be awindowwhere inhibition of themutant
allele will be sufficient to prevent or reverse formation of harmful
aggregation of polyglutamine fragments, whereas equivalent
inhibition of the wild-type protein preserves sufficient HTT for
essential normal functions. However, agents that preferentially
inhibit expression of mutant HTT might widen this therapeutic
window and improve treatment outcomes.
In our previous studies we examined inhibition of HTT expres-
sion by single-stranded oligomers targeting the CAG repeat (Hu
et al., 2009a, 2009b, 2009c). Our data were promising, with
significant allele selectivity being achieved by several different
chemically modified oligomers. Locked nucleic acid oligomers
(LNAs), a chemistry already being tested in the clinical Phase II
trials for treatment of other diseases (Koch et al., 2008), showed
up to 6-fold allele selectivity and provide a promising starting
point for further development (Hu et al., 2009c). However, after
exhaustively testing peptide nucleic acid (PNA), LNA, (S)-cET
bridged nucleic acid, carba-LNA, ethylene nucleic acid (ENA),
altritol nucleic acid (ANA), 20-O-methoxyethyl (MOE), 20-fluoro,
and 20-fluoroarabino nucleic acid (FANA) oligomers, we were
unable to identify any compound with better than 8-fold allele-
selectivity (Gagnon et al., 2010).
Our most effective single-stranded oligonucleotides inhibited
expression by blocking gene translation rather than causing
degradation of HTT mRNA. Because mismatched RNAs can
also function through the RNAi pathway by blocking translation,
we tested them and observed high levels of allele selectivity.
Importantly, this selectivity was not a property of only one or
two compounds. Several different arrangements of mismatched
bases were potent and selective inhibitors of gene expression,
including one compound with four contiguous mismatched
nucleotides. These RNA duplexes demonstrate an ample supply
of lead compounds to optimize for the potency, allele selectivity,
low toxicity, and biodistribution necessary for successful in vivo
application.Chemistry & Biology 17, 1183–118SIGNIFICANCE
Developing curative treatments for HD remains an urgent
unmet medical need. Reducing the amount of mutant
HTT would directly target the agent causing HD, and
duplex RNAs and antisense oligonucleotides have proven
to be effective in engineered animal models. The challenge
now is to improve the properties of anti-HTT nucleic acids
sufficiently to enable clinical trials in humans. One impor-
tant goal for improvement is identification of compounds
that preferentially reduce levels of mutant HTT while
preserving physiologically essential levels of wild-type
HTT.
Mismatch-containing RNAs reduce expression of
mutant HTT robustly, with low nanomolar potencies and
selectivities greater than 30 fold. Selective inhibition can
be achieved in cell lines with mutant alleles containing
low numbers of repeats, extending the approach to cell
culture models representing almost all of the human
patient population. The fact that several different com-
pounds are potent and selective offers several starting
points for the medicinal chemistry necessary to create
molecules that will have optimal potency, selectivity, and
biodistribution.
Beyond potential therapeutic application to HD, our work
has implications for understanding recognition of RNA
sequences during RNAi. The basic target sequence—
multiple CAGs—is the same regardless of whether the
repeat is expanded. The RISC complexes formed by duplex
RNAs must sense structural variations or relatively modest
differences in repeat length. This sensitivity can be trans-
lated into substantial improvements in recognition by a
diverse group of mismatch-containing RNA duplexes. Intro-
ducing mismatches may allow gene silencing to be fine-
tuned to achieve optimal results at specific RNA target
sequences and structures.EXPERIMENTAL PROCEDURES
Full details of materials and experimental procedures used in this study can be
found in the Supplemental Experimental Procedures.SUPPLEMENTAL INFORMATION
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